![ESMO23_Venue_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/general-pics/esmo23_venue_01/18322193-1-eng-GB/esmo23_venue_01_i770.jpg)
An ESMO study reveals that poor quality of real-world data from oncology studies is still an issue
Scarcity of prospective data was reported as well as a limited use of real-world evidence as definitive evidence to regulatory approval decisions of targeted therapies in Europe